Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Neurogen Biomarking
Chicago, Illinois, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Neurogen Biomarking has launched a commercial platform integrating at-home blood biomarker (pTau217) testing, AI-driven digital cognitive assessment, and telehealth-based neurologist care, validated through a beta program with >500 participants and exhibiting high satisfaction rates; prospective data will be presented at Alzheimer's Association International Conference 2025.
- Therapeutic areas
- Neurology
- Modalities
- Diagnostic testDigital cognitive assessmentDevice
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
AransciaAccessDx Laboratory2bPreciseLinus HealthNeuroXQuanterix
Beyond the preview
Go deeper on Neurogen Biomarking.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurogen Biomarking.